Navigation Links
UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
Date:11/5/2013

SYDNEY, Nov. 5, 2013 /PRNewswire/ -- UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer Institute (NCI) grant and will involve 48 individuals with definitively treated stage IIIA/B non-small cell lung cancer (NSCLC). A description of DPV-001, an "off-the-shelf vaccine," was presented by Dr. Helen Ross, Mayo Clinic Arizona, in an oral session (abstract #O-08.01). This next generation vaccine contains a system for targeting to dendritic cells, at least 9 cancer antigens prioritized by an NCI advisory panel and 5 toll-like receptor agonists to boost immunity. "Patients with locally advanced lung cancer still have a very high risk of cancer returning despite our most aggressive treatments," said Dr. Rachel Sanborn, the trial's principal investigator and the Co-Director of Thoracic Oncology, Providence Cancer Center, Portland, Oregon. "This novel vaccine approach may help the immune system recognize and fight remaining cancer cells." In a presentation of the Phase 1 trial in patients with Stage IV NSCLC, the authors reported that immune responses were detected in a majority of the evaluable patients (abstract # P-3.11-032).

"UbiVac is excited to pioneer this first-in-class vaccine technology to patients with NSCLC," said Dr. Hong-Ming Hu, inventor of autophagosome DRibble technology, Co-founder and CSO of UbiVac. "In addition to lung cancer, UbiVac is actively pursuing the application of this technology, with our partners and collaborators, for the treatment of head and neck, hepatocellular, prostate, colon and breast cancer."

UbiVac, spun-out from the Providence Health System in 2005, recently was judged by Oregon CEOs as the top "Presenting Company" at the Oregon Bioscience Association annual meeting has three vaccine platform technologies under development: DRibbles, a nanotechnology platform and a disabled cytomegalovirus (CMV) vector platform.

The ongoing activities reported in this release are supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CA165048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.


'/>"/>
SOURCE UbiVac
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotest Opens New Plasma Center in Melbourne, Florida
2. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
3. AdvaMed 2013: The MedTech Conference Opens Monday in Washington, D.C.
4. Unique Glaucoma Test Through Eyelid DIATON Opens Doctors Eyes to Possibility of In-Office Glaucoma Test at Pri-Med East and American Academy of Family Physicians, AAFP
5. Dr. George O. Gavrila Opens Baltimore Tattoo Removal, Offers Astanza Duality Laser Technology
6. Boston Scientific Opens Institute For Advancing Science, Innovation Center In Shanghai
7. BioReliance Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan
8. MinuteClinic Opens Its First Walk-in Medical Clinic in Southwest Virginia
9. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
10. Life Technologies Opens State-of-the-Art DNA Forensics Laboratory in India
11. MinuteClinic Opens Its First Medical Clinics in Lehigh Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):